Video

Educated Patient® Lung Cancer Summit: March 6, 2021

Author(s):

CURE staff

View the full CURE Educated Patient Lung Cancer Summit on demand.

Related Videos
a man and a woman in front of a dark blue background for CURE Speaking Out
a man and a woman in front of a dark blue background for CURE Speaking Out
a man and a woman in front of a dark blue background for CURE Speaking Out
a man and a woman in front of a dark blue background for CURE Speaking Out
Image of doctor with brown hair.
Image of Doctor with blonde hair.
Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients.
Dr. Neeraj Agarwal is a medical oncologist, a professor of medicine and the Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute, University of Utah, as well as director of the Genitourinary Oncology Program and the Center of Investigational Therapeutics at the Huntsman Cancer Institute in Salt Lake City.
Image of Dr. Goy.
Image of bald man.
Related Content
Illustration of lung.
March 6th 2025

Presurgical Opdivo Plus Yervoy Has Potential Clinical Benefit in NSCLC

Alex Biese
Among patients with resectable non-small cell lung cancer, Opdivo plus Yervoy has displayed potential long-term clinical benefits versus chemotherapy.
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
Illustration of woman with black hair.
February 27th 2025

My Cousin and I Journey Through Breast, Lung, Pancreatic and Prostate Cancer

Sue McCarthy
After realizing that a stronger support system would have helped me emotionally and spiritually in my cancer journey, I committed myself to being there for my cousin.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
Illustration of lung.
February 25th 2025

Neoadjuvant Opdivo Combo Elicits Statistically Significant OS Findings in Resectable NSCLC

Ryan Scott
Neoadjuvant Opdivo with platinum-doublet chemo had a statistically significant and clinically meaningful improvement versus chemo alone in resectable NSCLC.
Illustration of lung cancer.
February 24th 2025

Zongertinib Receives Priority Review For HER2 Mutant NSCLC

Spencer Feldman
Zongertinib, an investigational treatment for HER2-mutant advanced NSCLC, has received FDA priority review, showing positive results and favorable safety.